Omeros reports positive data from pivotal narsoplimab trial

Omeros (NASDAQ:OMER) reported positive data from its pivotal clinical trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).

HSCT-TMA occurs when blot clots form following a stem cell transplant, and in severe cases, the mortality rate can be more than 90%. 

The study’s primary efficacy endpoint is the proportion of patients who achieve improvements in both HSCT-TMA laboratory markers and clinical status. Of the patients who received at least one dose of narsoplimab, 56% achieved complete responder status. In patients who received the protocol-specified narsoplimab treatment of at least 4 weeks of dosing, 68% achieved complete responder status.

“The response rate in this high-risk population would be expected to be 10% to 15% with a 100-day survival rate of less than 20%,” Dr. Rafael Duarte, associate professor, head of hematology department and hematopoietic transplantation program, University Hospital Puerta de Hierro Majadahonda, said in a statement. 

“The response rate and 100-day survival achieved with narsoplimab in this trial demonstrate an unprecedented effect in this condition. The other secondary endpoints are equally impressive. I expect a treatment with this profile would be widely adopted for use in these patients and even lead to increased physician recognition of the disorder,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.